Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
May 21, 2001
- Santen Ties Up with PDI for Levofloxacin
May 21, 2001
- JMA to Start Monitoring Medical Facilities' Business Performance
May 21, 2001
- SSP, Nihon Tenganyaku to Jointly Research Antifungal Eye Drop
May 21, 2001
- \240,000 Necessary per Month forNursing Care: Survey Respondents
May 21, 2001
- Kissei Completes Therapeutic Nutritive Food Business Center
May 21, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2001
- Ethical Drugs Achieve 2.5% Growth in FY2000
May 21, 2001
- WORLD NEWS ON BRIEF
May 21, 2001
- Sankyo Stresses Fewer Drug Interactions for Mevalotin
May 21, 2001
- Sanofi-Synthelabo, Organon to Jointly Start PII for Pentasaccharide
May 21, 2001
- JPMA to Hold Int'l Panel Focusing on Patient-Oriented Healthcare
May 14, 2001
- Evidence on Acute Myocardial Infarctions in Japan Compiled by Korosho Study Group
May 14, 2001
- Wholesalers' FTC to Stop Members Supporting Medical Institution Social Gatherings
May 14, 2001
- Diagnostic, Treatment GL for Urinary Incontinence in Women Prepared
May 14, 2001
- BUSINESS NEWS IN BRIEF -2-
May 14, 2001
- Health Insurance Coverage for Viagra Demanded by the Public: Pfizer Seminar
May 14, 2001
- Kyowa Hakko Kogyo Aims at \300 Bil. Drug Sales in 2011: President Hirata
May 14, 2001
- 2hPG Recommended for Predicting Cardiovascular Disease Mortality: Takeda Seminar
May 14, 2001
- NBI to Increase Its Sales to \110 Bil. in 2004: President Kawabata
May 14, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…